Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
RWE 101 – The Evolution of Real World Evidence Regulations
RWE 101 - The Evolution of Real World Evidence Regulations Real-world evidence (RWE) has become an increasingly important source of data for regulatory decision-making in healthcare. The [...]
RWE 101 – Is Real World Evidence a Replacement for Clinical Trials?
RWE 101 - Is Real World Evidence a Replacement for Clinical Trials? Real world evidence (RWE) is not a replacement for clinical trials. Clinical trials are considered [...]
RWE 101 – How Robust is RWE?
RWE 101 - How Robust is RWE? Real world evidence (RWE) is evidence that is collected outside of traditional randomized controlled trials (RCTs), such as observational studies [...]
RWE 101 – What is the Connection between Real World Data (RWD) and Real World Evidence (RWE)?
RWE 101 - 4 Potential Uses for Improving Drug Development Real world data (RWD) refers to any data that is generated outside of a clinical trial setting, [...]
RWE 101 – The Role of RWE in the Context of Digital Health
RWE 101 - The Role of RWE in the Context of Digital Health Digital health refers to the use of digital technologies, such as mobile devices, wearables, [...]
RWE 101 – Purpose of Real World Evidence
RWE 101 - Purpose of Real World Evidence The purpose of real-world evidence (RWE) is to provide insights into the safety, effectiveness, and value of medical products [...]







